EL7.AI
StocksMedium•5 November 2026•
2 min read

Adicet Bio Posts Per-Share Loss of $1.76 in Third Quarter of 2026

Key Facts

1Basic and diluted loss per share was $1.76 in the third quarter of 2026, compared with $4.72 in the third quarter of 2025.
2Research and development expenses were $15.6 million, compared with $22.9 million in the year-earlier quarter.
350% of evaluable lupus nephritis patients achieved a complete renal response at 12 months, and the DORIS remission rate was 54%.
4ACET shares closed at $3.10 on November 4, 2026.

Adicet Bio reported results on November 5 for the third quarter ended September 30, 2026, posting a basic and diluted loss of $1.76 per share. The company said its loss per share in the same period of 2025 was $4.72. The results included a decline in research and development expenses to $15.6 million from $22.9 million a year earlier. General and administrative expenses also fell to $4.2 million, compared with $5.1 million in the third quarter of 2025. In trading on November 4, the company's shares closed at $3.10.

For its experimental prula-cel program to treat lupus, the company said 50% of evaluable patients with lupus nephritis achieved a complete renal response at 12 months. About 54% of evaluable patients achieved remission under the DORIS definition over the same period. These results came from a group of 22 patients evaluable for efficacy, based on data available through August 28, 2026. Sixteen of them had lupus nephritis, while 6 had systemic lupus outside the kidneys. Follow-up in the group ranged from 6 to 21 months.

Chief Executive Chen Schor said the prula-cel data strengthened the company's confidence in its potential to achieve durable remissions for lupus patients. He added that the company looked forward to "providing a regulatory update and additional follow-up data at 12 months for approximately 22 patients" in the first quarter of 2027. This timeline puts patient follow-up and a regulatory update among the program's upcoming milestones. The company also expects to report Phase 1 data evaluating prula-cel in systemic sclerosis during the second quarter of 2027. It also plans to begin enrolling patients in the ADI-212 trial for metastatic castration-resistant prostate cancer in the first quarter of 2027.

The announced development program extends beyond those trials: Adicet Bio plans to launch its first in vivo CAR-T program in the second half of 2027. That timeline is part of the company's announced schedule for upcoming programs. In the first quarter of 2027, the lupus program is expected to receive a regulatory update and additional follow-up data, Schor said. The company then expects systemic sclerosis data in the second quarter of the same year. Patient enrollment in the ADI-212 trial is expected to begin in the first quarter of 2027.

Open on chart